Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-05-22
2007-05-22
Duffy, Patricia A. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S391300, C530S391700
Reexamination Certificate
active
10293418
ABSTRACT:
The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.
REFERENCES:
patent: 6297367 (2001-10-01), Tribouley
patent: 6403770 (2002-06-01), Yu et al.
patent: 6562579 (2003-05-01), Yu et al.
patent: 2001/0010925 (2001-08-01), Wiley
patent: 2002/0055624 (2002-05-01), Wiley
patent: 2003/0012783 (2003-01-01), Kindsvogel
patent: 2003/0059937 (2003-03-01), Ruben et al.
patent: 2006/0062789 (2006-03-01), Ruben et al.
patent: 0869180 (1998-10-01), None
patent: 0921194 (1999-06-01), None
patent: WO97/33902 (1997-09-01), None
patent: WO98/18921 (1998-05-01), None
patent: WO98/27114 (1998-06-01), None
patent: WO98/55620 (1998-12-01), None
patent: WO98/55621 (1998-12-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO99/12964 (1999-03-01), None
patent: WO99/33980 (1999-07-01), None
patent: WO00/26244 (2000-05-01), None
patent: WO00/39295 (2000-07-01), None
patent: WO00/40716 (2000-07-01), None
patent: WO00/43032 (2000-07-01), None
patent: WO00/45836 (2000-08-01), None
patent: WO00/47740 (2000-08-01), None
patent: WO00/50597 (2000-08-01), None
patent: WO00/60079 (2000-10-01), None
patent: WO00/67034 (2000-11-01), None
patent: WO00/68378 (2000-11-01), None
patent: WO00/77256 (2000-12-01), None
patent: WO01/40466 (2001-06-01), None
patent: WO01/87977 (2001-11-01), None
Ashkenazi, et al., Response, Nature Immunology, (2000) 1:179.
Baumgarth, Nicole, Secreted IgM versus BLyS in Germinal Center Formation, Nature Immunology, (2000) 1:179.
Batten et al., BAFF Mediates Survival of Peripheral Immature B Lymphocytes. The Journal of Experimental Medicine, (2000) 192:1453-65.
Cheema et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, Arthritis and Rheumatism (2001) 44:1313-1319.
Cyster, Jason G., B Cells on the Front Line, Nature Immunology, (2000) 1:9-10.
Do et al., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, The Journal of Experimental Medicine, (2000) 192:953-964.
Dorner and Putterman, B cells, BAFF/zTNF4, TACI, and Systemic Lupus Erythematosus, Arthritis Research (2001) 3:197-9.
Gross et al., TACI and BCMA are receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease, Nature, (2000) 404:995-999.
Hatzoglou et al., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-kB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330.
Hu et al., Characterization of TNFRSF 19, a Novel Member of the Tumor Necrosis Factor Receptor Superfamily, Genomics, 62:1023-107 (1999).
Khare et al., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, The Proceedings of the National Academy of Sciences, (2000) 97:3370-3375.
Laabi et al., Lymphocyte Survival-Ignorance is BLyS, Science, (2001) 289:883.
Mackay et al., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, The Journal of Experimental Medicine, (1999) 190:1697-1710.
Marsters, et al., Interaction of the TNF Homologues BLyS and APRIL with the TNF Receptor Homologues BCMA and TACI, Current Biology, (2000) 10:785-788.
Moore et al., BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285:260-263.
Mukhopadhay et al., Identification and Characterization of a Novel Cytokine, THANK, A TNF Homologue That Activates Apoptosis, Nuclear Factor-KB, and c-Jun NH2 Terminal Kinase (1999) The Journal of Biological Chemistry 274:15978-81.
Nardelli et al., Synthesis and Release of B-lymphocyte Stimulator from Myeloid Cells, Blood, (2001) 97:198-204.
Parry et al., Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BLyS) in Mice, The Journal of Pharmacology and Experimental Therapeutics, (2001) 296:396-404.
Schneider et al., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, The Journal of Experimental Medicine, (1999) 189:1747-1756.
Shu et al., TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens, Journal of Leukocyte Biology, (1999) 65:680-683.
Thompson et al., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, The Journal of Experimental Medicine, (2000) 192:129-135.
Tribouley et al, Characterization of a New Member of the TNF Family Expressed on Antigen Presenting Cells, (1999) Biological Chemistry 380:1443-7.
Ware, Carl, APRIL and BAFF Connect Autoimmunity and Cancer. The Journal of Experimental Medicine (2000) 192:F35-F37.
Xia et al., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, The Journal of Experimental Medicine, (2000) 192:137-143.
Yan et al., Identification of a receptor for BLyS Demonstrates a Crucial Role in Humoral Immunity, Nature Immunology, (2000) 1:37-41.
Yu et al., APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity, Nature Immunology, (2000) 1:252-256.
Zhang et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, (2001) 166:6-10.
Kanakaraj et al., BLyS Binds to B Cells WIth High Affinity and Induces Activation of the Transcription Factors NF-kB and Elf-1, Cytokine (2001) 13:25-31.
Wu et al., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BLyS, The Journal of Biological Chemistry (2000) 275:35478-35485.
Kabat et al., Sequences of Proteins of Immunological Interest, Fourth Edition, pp. 44, 53-54, 63, 69-70, and 76 (1987).
Choi Gil H.
Hilbert David
Ruben Steven M.
Vaughan Tristan
Duffy Patricia A.
Human Genome Sciences Inc.
LandOfFree
Antibodies that immunospecifically bind to B lymphocyte... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that immunospecifically bind to B lymphocyte..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that immunospecifically bind to B lymphocyte... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3798540